Gene Polymorphisms Affect Postoperative Imatinib Plasma Levels and Edema in Adults With Gastrointestinal Stromal Tumor

References

• Blay JY , KangYK , NishidaT , von MehrenM. Gastrointestinal stromal tumours. Nat. Rev. Dis. Primers.7(1), 22 (2021).
   PubMed Web of Science ®Google Scholar
• Inayat F , SaifMW. New drug and possible new toxicity – squamous cell carcinoma following imatinib in patients with gastrointestinal stromal tumors. Anticancer Res.36(11), 6201–6204 (2016).
   PubMed Web of Science ®Google Scholar
• Joensuu H , HohenbergerP , CorlessCL. Gastrointestinal stromal tumour. Lancet382(9896), 973–983 (2013).
   PubMed Web of Science ®Google Scholar
• Casali PG , LeCesne A , PovedaVelasco Aet al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J. Clin. Oncol.33(36), 4276–4283 (2015).
   PubMed Web of Science ®Google Scholar
• Verboom MC , KlothJSL , SwenJJet al. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J.19(5), 473–479 (2019).
   PubMed Web of Science ®Google Scholar
• Xia Y , ChenS , LuoMet al. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors. Cancer126(Suppl. 9), 2054–2061 (2020).
   PubMedGoogle Scholar
• Menon-Andersen D , MondickJT , JayaramanBet al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother. Pharmacol.63(2), 229–238 (2009).
   PubMed Web of Science ®Google Scholar
• Westerdijk K , DesarIME , SteeghsNet al. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br. J. Clin. Pharmacol.86(2), 258–273 (2020).
   PubMed Web of Science ®Google Scholar
• Evans WE , McLeodHL. Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348(6), 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang Q , XuJ , QianYet al. Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors. Mol. Cancer Ther.17(12), 2780–2787 (2018).
   PubMed Web of Science ®Google Scholar
• Lander ES . The new genomics: global views of biology. Science274(5287), 536–539 (1996).
   PubMed Web of Science ®Google Scholar
• Bhatti MT , SalamaAKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye32(2), 287–301 (2018).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP , BallmanKV , AntonescuCRet al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet373(9669), 1097–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Liu J , ChenZ , ChenHet al. Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients. Int. J. Mol. Sci.18(3), 603 (2017).
   PubMed Web of Science ®Google Scholar
• Sobel RK , CarterKD , AllenRC. Periorbital edema: a puzzle no more?Curr. Opin. Ophthalmol.23(5), 405–414 (2012).
   PubMed Web of Science ®Google Scholar
• Qiu HB , ZhuangW , WuTet al. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J.18(3), 460–466 (2018).
   PubMed Web of Science ®Google Scholar
• Li J , WangM , ZhangBet al. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J. Gastroenterol.24(46), 5189–5202 (2018).
   PubMed Web of Science ®Google Scholar
• Stoll DR , LiX , WangX , CarrPW , PorterSE , RutanSC. Fast, comprehensive two-dimensional liquid chromatography. J. Chromatogr. A1168(1–2), 3–43 (2007).
   PubMed Web of Science ®Google Scholar
• Xu Q , XuL , ZhangMet al. Influence of NFATC1 Polymorphisms on the Incidence of Chronic Rejection in Renal Transplant Patients. Chinese Journal of Pharmacoepidemiology.29(06), 413–420 (2020).
   Google Scholar
• Van Glabbeke M , VerweijJ , CasaliPGet al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur. J. Cancer42(14), 2277–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Liu X , QiuH , ZhangPet al. Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers. Chin. J. Cancer Res.30(1), 61–71 (2018).
   PubMed Web of Science ®Google Scholar
• Xu H , LiuQ. Individualized management of blood concentration in patients with gastrointestinal stromal tumors. Onco Targets Ther.13, 13345–13355 (2020).
   PubMed Web of Science ®Google Scholar
• Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol.39(10), 1411–1419 (2008).
   PubMed Web of Science ®Google Scholar
• Heuchel R , BergA , TallquistMet al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl Acad. Sci. USA96(20), 11410–11415 (1999).
   PubMed Web of Science ®Google Scholar
• Esmaeli B , PrietoVG , ButlerCEet al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer95(4), 881–887 (2002).
   PubMed Web of Science ®Google Scholar
• Pietras K , OstmanA , SjoquistMet al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res.61(7), 2929–2934 (2001).
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S , ColletteL , PaolettiXet al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur. J. Cancer50(12), 2040–2049 (2014).
   PubMed Web of Science ®Google Scholar
• Wozniak A , RutkowskiP , PiskorzAet al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann. Oncol.23(2), 353–360 (2012).
   PubMed Web of Science ®Google Scholar
• Ushimaru Y , TakahashiT , NakajimaKet al. Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence. Int. J. Clin. Oncol.27(5), 921–929 (2022).
   PubMed Web of Science ®Google Scholar
• Patrikidou A , ChabaudS , Ray-CoquardIet al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann. Oncol.24(4), 1087–1093 (2013).
   PubMed Web of Science ®Google Scholar
• Joensuu H , TrentJC , ReichardtP. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat. Rev.37(1), 75–88 (2011).
   PubMed Web of Science ®Google Scholar
• Chin-Yee B , XenocostasA. Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor. Ann. Hematol.101(6), 1373–1374 (2022).
   PubMed Web of Science ®Google Scholar
• Koo DH , RyuMH , RyooBYet al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemother. Pharmacol.75(1), 173–182 (2015).
   PubMed Web of Science ®Google Scholar
• Dulucq S , KrajinovicM. The pharmacogenetics of imanitib.Genome. Med.2(11), 85 (2010).
   PubMedGoogle Scholar
• Kimchi-Sarfaty C , OhJM , KimIWet al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science.315(5811), 525–528 (2007).
   PubMed Web of Science ®Google Scholar
• Druker BJ , TamuraS , BuchdungerEet al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med.2(5), 561–566 (1996).
   PubMed Web of Science ®Google Scholar
• Liu J , XiH , JiangYet al. Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy. Acta Anaesth. Scand.59(5), 640–647 (2015).
   PubMed Web of Science ®Google Scholar